QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garrelts, J. C Articles by Harrison, P. B Search for Related Content PubMed PubMed Citation Articles by Garrelts, J. C Articles by Harrison, P. B

CRITICAL CARE

Impact of Fluconazole Administration on Outcomes in Critically Ill Patients

Manager, Clinical Pharmacy Services and Research, Wesley Medical Center, Wichita, KS

Todd R Schroeder, PharmD

Clinical Pharmacy Specialist, Infectious Diseases, Wesley Medical Center

Paul B Harrison, MD

Director, Trauma Program, Wesley Medical Center

Reprints: James C Garrelts PharmD, Wesley Medical Center, 550 N. Hillside, Wichita, KS 67214-4976, fax 316/962-2568, Jim.Garrelts{at}wesleymc.com

BACKGROUND: Serious infections caused by Candida spp. are an increasingly important cause of morbidity and mortality in critically ill patients. It is unclear which patients will benefit from therapy and at what point to institute treatment.

OBJECTIVE: To evaluate the impact of administration of fluconazole therapy in critically ill trauma patients on mortality, length of hospital stay, incidence of deep-seated fungal infection, and positive fungal cultures from any site.

METHODS: We conducted a retrospective, matched case–control study of 116 critically ill surgical trauma patients who did or did not receive fluconazole. Patients were followed until hospital discharge or death. A consecutive sample of 58 patients who received fluconazole was selected. A parallel group of patients was evaluated, from which 58 were matched with fluconazole-treated patients based on age (± 5 y), gender, and APACHE II score (± 3).

RESULTS: The groups of patients were well matched, with the exception of central venous catheter placement and broad-spectrum antibiotic use. We found no difference between groups in hospital mortality (21% vs 26%; p = 0.661) or incidence of deep-seated fungal infection (0% vs 2%; p = NS). However, patients receiving fluconazole had a significantly longer stay in both the intensive care unit (ICU) (18 ± 13 vs 7 ± 11 days; p < 0.001) and hospital (25 ± 15 vs 9 ± 11 days; p < 0.001). Fluconazole patients were significantly more likely to have Candida cultured from sites associated with colonization (43% vs 2%; p < 0.001), possibly explaining why they received fluconazole.

CONCLUSIONS: We were unable to detect a benefit from use of fluconazole in our surgical trauma patient population. Isolation of Candida from the mouth or throat alone, in the absence of correlating clinical signs of infection, should not lead to initiation of fluconazole therapy. Fluconazole use should be reserved for carefully selected patients in the trauma ICU setting.

Key Words: fluconazole, outcomes, trauma

Published Online, August 31, 2004. www.theannals.com, DOI 10.1345/aph.1D441

This article has been cited by other articles:

				R. Tsuruta, H. Mizuno, T. Kaneko, Y. Oda, K. Kaneda, M. Fujita, T. Inoue, S. Kasaoka, and T. Maekawa Preemptive Therapy in Nonneutropenic Patients with Candida Infection Using the Japanese Guidelines Ann. Pharmacother., July 1, 2007; 41(7): 1137 - 1143. [Abstract] [Full Text] [PDF]